Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT05000450 · TERMINATED
Trial details
- NCT number
- NCT05000450
- Sponsor
- Allogene Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-06
- Primary completion
- 2023-10-11
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.